
Oxford Immunotec Global PLC OXFD
Oxford Immunotec Global PLC Deferred Revenue 2011-2026 | OXFD
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Oxford Immunotec Global PLC
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | 19 K | 125 K | 36 K | 41 K | 1.65 M | 1.99 M | 1.54 M | 908 K | 71 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.99 M | 19 K | 710 K |
Deferred Revenue of other stocks in the Diagnostics research industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.34 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
7.53 M | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
1.54 M | $ 13.71 | -0.22 % | $ 99.4 M | ||
|
Aspira Women's Health
AWH
|
489 K | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
955 K | $ 8.62 | 0.23 % | $ 574 M | ||
|
Charles River Laboratories International
CRL
|
210 M | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Castle Biosciences
CSTL
|
6.62 M | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
4.65 M | $ 17.01 | 3.4 % | $ 906 M | ||
|
DexCom
DXCM
|
10.1 M | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Accelerate Diagnostics
AXDX
|
547 K | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
4.14 M | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Global Cord Blood Corporation
CO
|
458 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
13.5 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
77.3 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
8.42 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
2.23 M | $ 14.77 | 0.61 % | $ 447 M | ||
|
Guardant Health
GH
|
50.8 M | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
733 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
678 K | $ 17.88 | -6.63 % | $ 2.32 B | ||
|
Anixa Biosciences
ANIX
|
1.19 M | $ 2.83 | -1.05 % | $ 91.8 K | ||
|
Heska Corporation
HSKA
|
5.08 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
185 K | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
1.61 B | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Danaher Corporation
DHR
|
1.35 B | $ 187.32 | 0.57 % | $ 134 B | ||
|
IQVIA Holdings
IQV
|
2.12 B | $ 164.72 | 1.1 % | $ 28.3 B | ||
|
Illumina
ILMN
|
260 M | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
QIAGEN N.V.
QGEN
|
57.1 M | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
441 M | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
1.13 M | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
997 K | $ 9.0 | -0.99 % | $ 255 M | ||
|
Mettler-Toledo International
MTD
|
122 M | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Chembio Diagnostics
CEMI
|
1.61 M | - | 0.22 % | $ 16.8 M | ||
|
Neogen Corporation
NEOG
|
5.56 M | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
Co-Diagnostics
CODX
|
362 K | - | - | $ 79.8 M | ||
|
Medpace Holdings
MEDP
|
854 M | $ 450.41 | 1.48 % | $ 13 B | ||
|
National Research Corporation
NRC
|
16.2 M | $ 16.52 | 0.12 % | $ 370 M | ||
|
DermTech
DMTK
|
196 K | - | -11.32 % | $ 2.94 M | ||
|
Invitae Corporation
NVTA
|
4.81 M | - | - | $ 21.2 M | ||
|
NeoGenomics
NEO
|
851 K | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
2.68 M | - | -8.98 % | $ 14.8 K | ||
|
OPKO Health
OPK
|
6 K | $ 1.19 | 2.59 % | $ 826 M | ||
|
Natera
NTRA
|
10.8 M | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Myriad Genetics
MYGN
|
32.7 M | $ 4.66 | -3.92 % | $ 432 M | ||
|
Pacific Biosciences of California
PACB
|
15.9 M | $ 1.33 | 4.72 % | $ 399 M |